{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:22:46Z","timestamp":1792592566145,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["48579"],"award-info":[{"award-number":["48579"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jpet.2025.103749","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:16:10Z","timestamp":1760393770000},"page":"103749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mitigation of thromboinflammation by rivaroxaban ameliorates metabolic and structural manifestations of metabolic dysfunction\u2013associated steatohepatitis in rats: Comparison to other antithrombotic drugs"],"prefix":"10.1016","volume":"392","author":[{"given":"Basant","family":"Rageh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marium","family":"Shamaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-2819","authenticated-orcid":false,"given":"Mahmoud","family":"Agami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-3038","authenticated-orcid":false,"given":"Ahmed F.","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpet.2025.103749_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jpet.2025.103749_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103749_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/hep.20569","article-title":"Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests","volume":"41","author":"Tripodi","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jpet.2025.103749_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103749_bib6","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.jtha.2024.08.023","article-title":"Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis","volume":"22","author":"Pandey","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.jpet.2025.103749_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/met.2015.0061","article-title":"Increased RhoA\/Rho-kinase activity and markers of endothelial dysfunction in young adult subjects with metabolic syndrome","volume":"13","author":"Leguina-Ruzzi","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"issue":"2","key":"10.1016\/j.jpet.2025.103749_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/1479164116679080","article-title":"Procoagulant activity in patients with combined type 2 diabetes and coronary artery disease: no effects of long-term exercise training","volume":"14","author":"Bratseth","year":"2017","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103749_bib9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/ATVBAHA.115.305377","article-title":"Vascular smooth muscle cells are responsible for a prothrombotic phenotype of spontaneously hypertensive rat arteries","volume":"35","author":"Ait Aissa","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.jpet.2025.103749_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103749_bib11","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1172\/JCI116031","article-title":"Thrombin receptor expression in normal and atherosclerotic human arteries","volume":"90","author":"Nelken","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpet.2025.103749_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122225","article-title":"Periprostatic adipose tissue thromboinflammation triggers prostatic neoplasia in early metabolic impairment: interruption by rivaroxaban","volume":"334","author":"AlZaim","year":"2023","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103749_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1042\/CS20231186","article-title":"Interruption of perivascular and perirenal adipose tissue thromboinflammation rescues prediabetic cardioautonomic and renovascular deterioration","volume":"138","author":"Al-Saidi","year":"2024","journal-title":"Clin Sci (Lond)"},{"issue":"8","key":"10.1016\/j.jpet.2025.103749_bib14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1042\/CS20201445","article-title":"The pleiotropic effects of antithrombotic drugs in the metabolic-cardiovascular-neurodegenerative disease continuum: impact beyond reduced clotting","volume":"135","author":"Alaaeddine","year":"2021","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103749_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jpet.2025.103749_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1018710526772","article-title":"Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization","volume":"9","author":"Spencer","year":"2000","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10.1016\/j.jpet.2025.103749_bib17","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/fsn3.4010","article-title":"Silymarin: unveiling its pharmacological spectrum and therapeutic potential in liver diseases \u2013 a comprehensive narrative review","volume":"12","author":"Jaffar","year":"2024","journal-title":"Food Sci Nutr"},{"key":"10.1016\/j.jpet.2025.103749_bib18","series-title":"A proposed computational workflow for bioinformatics-based drug repurposing: a case study of canagliflozin","first-page":"224","author":"El-Nikhely","year":"2024"},{"key":"10.1016\/j.jpet.2025.103749_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/615917","article-title":"Estrogen signaling in metabolic inflammation","volume":"2014","author":"Monteiro","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jpet.2025.103749_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120956","article-title":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","volume":"308","author":"Shaaban","year":"2022","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103749_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jmf.2013.0179","article-title":"Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl4-treated rats","volume":"18","author":"Clichici","year":"2015","journal-title":"J Med Food"},{"issue":"10","key":"10.1016\/j.jpet.2025.103749_bib22","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.06.003","article-title":"Thrombolysis with rt-PA under rivaroxaban anticoagulation in a hypertensive rat model of intraluminal middle cerebral artery occlusion","volume":"27","author":"Izuma","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"5","key":"10.1016\/j.jpet.2025.103749_bib23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10620-006-9595-1","article-title":"The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis","volume":"52","author":"Assy","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21608\/bvmj.2021.65036.1346","article-title":"Therapeutic potential and hepatoprotective activity of proanthocyanidin and clopidogrel in non-alcoholic fatty liver disease-induced rats","volume":"40","author":"Hussein","year":"2021","journal-title":"Benha Vet Med J"},{"issue":"16","key":"10.1016\/j.jpet.2025.103749_bib25","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.3390\/molecules27165327","article-title":"Mechanistic insights into the pharmacological significance of silymarin","volume":"27","author":"Wadhwa","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.jpet.2025.103749_bib26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jpet.2025.103749_bib27","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.cgh.2020.11.005","article-title":"Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD","volume":"19","author":"Tamaki","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jpet.2025.103749_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcmd.2017.06.002","article-title":"Moderate exercise training decreases inflammation in transgenic sickle cell mice","volume":"69","author":"Charrin","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-0043-1768067","article-title":"Color deconvolution as a simple and rapid tool in quantitative biomedical research","volume":"14","author":"Nucci","year":"2024","journal-title":"J Health Allied Sci NU"},{"issue":"11","key":"10.1016\/j.jpet.2025.103749_bib30","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.7150\/ijbs.27173","article-title":"The PI3K\/AKT pathway in obesity and type 2 diabetes","volume":"14","author":"Huang","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jpet.2025.103749_bib31","article-title":"The role of PI3k\/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review","volume":"11","author":"Shamsan","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103749_bib32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2013an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s42826-024-00194-7","article-title":"Age-related changes in hematological and biochemical profiles of Wistar rats","volume":"40","author":"Patel","year":"2024","journal-title":"Lab Anim Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103749_bib34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1515\/mr-2022-0024","article-title":"Challenges and opportunities in nonalcoholic steatohepatitis","volume":"2","author":"Wang","year":"2021","journal-title":"Med Rev"},{"issue":"6","key":"10.1016\/j.jpet.2025.103749_bib35","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/j.gastro.2009.08.045","article-title":"An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis","volume":"137","author":"Tripodi","year":"2009","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.jpet.2025.103749_bib36","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.thromres.2008.11.008","article-title":"The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters","volume":"124","author":"Tripodi","year":"2009","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103749_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00281-021-00876-7","article-title":"The contact system in liver injury","volume":"43","author":"Rangaswamy","year":"2021","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib40","first-page":"93","article-title":"Role of perturbated hemostasis in MASLD and its correlation with adipokines","volume":"14","author":"Pezzino","year":"2024","journal-title":"Life (Basel)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103749_bib41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","article-title":"The interactions between inflammation and coagulation","volume":"131","author":"Esmon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jpet.2025.103749_bib42","article-title":"Tissue factor, blood coagulation, and beyond: an overview","volume":"2011","author":"Chu","year":"2011","journal-title":"Int J Inflam"},{"issue":"9","key":"10.1016\/j.jpet.2025.103749_bib43","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/gutjnl-2011-301857","article-title":"NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease","volume":"61","author":"Syn","year":"2012","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jpet.2025.103749_bib44","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000434","article-title":"An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD","volume":"8","author":"Zhang","year":"2024","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/path.4829","article-title":"Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances","volume":"241","author":"Lau","year":"2017","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103749_bib46","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.21874","article-title":"Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet","volume":"46","author":"Matsuzawa","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jpet.2025.103749_bib47","first-page":"1073","article-title":"Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD)","volume":"8","author":"Ni","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jpet.2025.103749_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trsl.2019.07.009","article-title":"Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs","volume":"214","author":"Elkhatib","year":"2019","journal-title":"Transl Res"},{"key":"10.1016\/j.jpet.2025.103749_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114041","article-title":"Dysfunctional cerebrovascular tone contributes to cognitive impairment in a non-obese rat model of prediabetic challenge: role of suppression of autophagy and modulation by anti-diabetic drugs","volume":"178","author":"Fakih","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpet.2025.103749_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114491","article-title":"Peri-renal adipose inflammation contributes to renal dysfunction in a non-obese prediabetic rat model: role of anti-diabetic drugs","volume":"186","author":"Hammoud","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib51","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1055\/s-0040-1701206","article-title":"Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial","volume":"4","author":"Kirchhof","year":"2020","journal-title":"TH Open"},{"issue":"4","key":"10.1016\/j.jpet.2025.103749_bib52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.thromres.2014.01.019","article-title":"Low molecular weight heparin-induced increase in chylomicron-remnants clearance, is associated with decreased plasma TNF-\u03b1 level and increased hepatic lipase activity","volume":"133","author":"Grosskopf","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.jpet.2025.103749_bib53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103749_bib54","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jpet.2025.103749_bib55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpet.2025.103749_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.597648","article-title":"Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies","volume":"11","author":"Luci","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jpet.2025.103749_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.yjmcc.2018.09.003","article-title":"Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis","volume":"123","author":"Chung","year":"2018","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib58","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12876-018-0789-8","article-title":"Thrombin and factor Xa link the coagulation system with liver fibrosis","volume":"18","author":"Dhar","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103749_bib59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2018-07-818211","article-title":"The multifaceted role of fibrinogen in tissue injury and inflammation","volume":"133","author":"Luyendyk","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jpet.2025.103749_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban\u2013an oral, direct Factor Xa inhibitor\u2013compared with other anticoagulants","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.jpet.2025.103749_bib61","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jpet.2025.103749_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jpet.2025.103749_bib63","first-page":"488","article-title":"Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin","volume":"88","author":"Storey","year":"2002","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.jpet.2025.103749_bib64","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/01.ATV.0000225288.74170.dc","article-title":"Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects","volume":"26","author":"Heitzer","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl_1","key":"10.1016\/j.jpet.2025.103749_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.10233","article-title":"Abstract 10233: interruption of perirenal adipose tissue thromboinflammation reverses prediabetic kidney impairment","volume":"144","author":"Al-Saidi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103749_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.715354","article-title":"Rivaroxaban modulates TLR4\/Myd88\/NF-K\u03b2 signaling pathway in a dose-dependent manner with suppression of oxidative stress and inflammation in an experimental model of depression","volume":"12","author":"Abdelzaher","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103749_bib67","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-008-1453-8","article-title":"MDMA: on the translation from rodent to human dosing","volume":"204","author":"Green","year":"2009","journal-title":"Psychopharmacology (Berl)"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:12:57Z","timestamp":1773918777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0022356525402626"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103749","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigation of thromboinflammation by rivaroxaban ameliorates metabolic and structural manifestations of metabolic dysfunction\u2013associated steatohepatitis in rats: Comparison to other antithrombotic drugs","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103749"}}